Events

Akari Therapeutics Fourth Quarter and Full Year 2017 Results Conference Call

March 21, 2018 at 8:30 AM EDT

Supporting Materials

AKTX Q4 2017 Results Conference Call Presentation 717.8 KB

Print Page
Email Alerts
RSS Feeds
Contact Us

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Akari TX

Events

Akari Therapeutics Fourth Quarter and Full Year 2017 Results Conference Call

March 21, 2018 at 8:30 AM EDT

Supporting Materials

LONDON

NEW YORK

EXPANDED ACCESS POLICY

Skip links

Events

Akari Therapeutics Fourth Quarter and Full Year 2017 Results Conference Call

March 21, 2018 at 8:30 AM EDT

Supporting Materials

Footer

LONDON

NEW YORK

EXPANDED ACCESS POLICY